Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Zijin Gold International / Equity Capital Markets

<ul>
<li>Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.</li>
<li>On the IPO front, all of the listings this week ended up doing well.</li>
<li>On the placements front, given the holiday shortened week in Hong Kong and India, there were no major placements this week.</li>
</ul>


Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
On the IPO front, all of the listings this week ended up doing well.
On the placements front, given the holiday shortened week in Hong Kong and India, there were no major placements this week.


ECM Weekly (6 October 2025)- Zijin, Myungin, Pateo,Tekscend, Tata Capital, LG India, WeWork, Impact

APAC IPOs & Placements, Aequitas Research

Nicholas Tan

APAC IPOs & Placements

Myungin Pharmaceutical / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/myungin-pharmaceutical" target="_blank" data-smartkarma-citation="entities:45685:1" rel="noopener">Myungin Pharmaceutical (MYUNGIN KS)</a> raised around US$142m in its upcoming Korean IPO.</li>
<li>It specializes in central nervous system (CNS) therapeutics, with strong technological expertise in developing and producing prescription drugs for stroke, Parkinson’s disease, schizophrenia, and depression.</li>
<li>In this note, we talk about the firm's trading dynamics.</li>
</ul>



Myungin Pharmaceutical (MYUNGIN KS) raised around US$142m in its upcoming Korean IPO.
It specializes in central nervous system (CNS) therapeutics, with strong technological expertise in developing and producing prescription drugs for stroke, Parkinson’s disease, schizophrenia, and depression.
In this note, we talk about the firm's trading dynamics.


Myungin Pharma Pre-IPO: Strong Insti Subscription Rates

Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Douglas Research Advisory

<ul>
<li>Myungin Pharm's IPO price has been confirmed at 58,000 won, which is at the high end of the IPO price range.</li>
<li>A total of 2,028 domestic and foreign institutional investors participated in the IPO demand forecast. The demand ratio was 488.9 to 1.</li>
<li>Our base case valuation of Myungin Pharm is market cap of 1.2 trillion won, and target price of 80,349 won per share, which is 39% higher than the IPO price.</li>
</ul>


Myungin Pharm's IPO price has been confirmed at 58,000 won, which is at the high end of the IPO price range.
A total of 2,028 domestic and foreign institutional investors participated in the IPO demand forecast. The demand ratio was 488.9 to 1.
Our base case valuation of Myungin Pharm is market cap of 1.2 trillion won, and target price of 80,349 won per share, which is 39% higher than the IPO price.


Myungin Pharmaceutical IPO Bookbuilding Analysis

<ul>
<li>Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.</li>
<li>On the IPO front, things are picking up going into the year end, as is usual, with multiple US$1bn+ deals said to go live over the next few weeks.</li>
<li>On the placements front, as well, market remains receptive for both primary and secondary offerings.</li>
</ul>


Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
On the IPO front, things are picking up going into the year end, as is usual, with multiple US$1bn+ deals said to go live over the next few weeks.
On the placements front, as well, market remains receptive for both primary and secondary offerings.


ECM Weekly (15 September 2025)- Chery, Zijin Gold, Hesai, Orion, Myungin, Urban, Nio, Kotak, Toei

<ul>
<li>
<a href="https://www.smartkarma.com/entities/myungin-pharmaceutical" target="_blank" data-smartkarma-citation="entities:45685:1" rel="noopener">Myungin Pharmaceutical (MYUNGIN KS)</a> is looking to raise up to US$142m in its upcoming Korean IPO.</li>
<li>It specializes in central nervous system (CNS) therapeutics and boasts an extensive product line-up of over 200 CNS products. </li>
<li>In this note, we examine the IPO dynamics, and look at the firm’s valuation.</li>
</ul>



Myungin Pharmaceutical (MYUNGIN KS) is looking to raise up to US$142m in its upcoming Korean IPO.
It specializes in central nervous system (CNS) therapeutics and boasts an extensive product line-up of over 200 CNS products. 
In this note, we examine the IPO dynamics, and look at the firm’s valuation.


Myungin Pharm Pre-IPO: Discount to Peers; Potential Succession Planning

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Myungin Pharmaceutical (MYUNGIN KS)

ECM Weekly (6 October 2025)- Zijin, Myungin, Pateo,Tekscend, Tata Capital, LG India, WeWork, Impact

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Myungin Pharma Pre-IPO: Strong Insti Subscription Rates

Myungin Pharmaceutical raised $142m in Korean IPO, specializing in CNS therapeutics with expertise in drugs for stroke, Parkinson's,...

Nicholas Tan

Myungin Pharmaceutical IPO Bookbuilding Analysis

Myungin Pharm's IPO price has been confirmed at 58,000 won, which is at the high end of the IPO price range. The demand ratio was 488.9 to 1.

Douglas Kim

ECM Weekly (15 September 2025)- Chery, Zijin Gold, Hesai, Orion, Myungin, Urban, Nio, Kotak, Toei

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Myungin Pharm Pre-IPO: Discount to Peers; Potential Succession Planning

Myungin Pharm is looking to raise up to US$142m in its upcoming Korean IPO. In this note, we examine the IPO dynamics, and look at the firm’s...

Nicholas Tan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

ECM Weekly (6 October 2025)- Zijin, Myungin, Pateo,Tekscend, Tata Capital, LG India, WeWork, Impact

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Myungin Pharma Pre-IPO: Strong Insti Subscription Rates

​Myungin Pharmaceutical raised $142m in Korean IPO, specializing in CNS therapeutics with expertise in drugs for stroke, Parkinson's,...

Nicholas Tan

Myungin Pharmaceutical IPO Bookbuilding Analysis

Myungin Pharm's IPO price has been confirmed at 58,000 won, which is at the high end of the IPO price range. The demand ratio was 488.9 to 1.

Douglas Kim

ECM Weekly (15 September 2025)- Chery, Zijin Gold, Hesai, Orion, Myungin, Urban, Nio, Kotak, Toei

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Myungin Pharm Pre-IPO: Discount to Peers; Potential Succession Planning

Myungin Pharm is looking to raise up to US$142m in its upcoming Korean IPO. In this note, we examine the IPO dynamics, and look at the firm’s...

Nicholas Tan

Myungin Pharmaceutical raised $142m in Korean IPO, specializing in CNS therapeutics with expertise in drugs for stroke, Parkinson's,...